Ophthalmic manifestation after SARS-CoV-2 vaccination: a case series

Murgova, Snezhana; G, Balchev

doi:10.1186/s12348-022-00298-y

Cited by 10 publications

(6 citation statements)

References 19 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 65 studies were both qualitatively and quantitatively analyzed ( Table 1 ) [ 1 , 5 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ,…”

Section: Resultsmentioning

confidence: 99%

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

et al. 2022

View full text Add to dashboard Cite

Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized with emphasis on patients’ characteristics [age, gender], vaccination characteristics [type, dose], and outcome findings [type, nature, laterality, course, location, onset, underlying cause, and associated findings]. Data are presented as numbers (percentages) for categorical data and as mean (standard deviation) for continuous data. Sixty-five studies were finally included [43 case reports, 16 case series, four cohort, one cross-sectional, and one registry-based study]. VAU occurred in 1526 cases, most commonly in females (68.93%) and middle-aged individuals (41–50 years: 19.71%), following the first dose (49.35%) of vaccination, especially in those who received Pfizer (77.90%). VAU occurred acutely (71.77%) as an inflammatory reaction (88.29%) in unilateral eyes (77.69%), particularly in the anterior portion of the uvea (54.13%). Importantly, most cases had a new onset (69.92%) while only a limited portion of cases had a reactivation of previous uveitis condition. In conclusion, although rare, uveitis following COVID-19 vaccination should be considered in new-onset and recurrent cases presenting with either acute or chronic events.

show abstract

Section: Resultsmentioning

confidence: 99%

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Optic neuropathy is suspected as one of adverse events of the COVID-19 vaccine, which includes ON associated with or without demyelinating CNS diseases [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ], NA-AION [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ], and NMOSD [ 8 , 9 ]. Lotan et al reviewed 14 case reports and 2 case series by electronic searches of the published literature regarding neuro-ophthalmological complications of COVID-19 vaccines and reported that optic neuritis was the most common, occurring in 61 of 76 cases (80.3%) [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

A Case of Atypical Unilateral Optic Neuritis Following BNT162b2 mRNA COVID-19 Vaccination

2022

View full text Add to dashboard Cite

Background: We report a case of atypical unilateral optic neuritis after receiving the BNT162b2 mRNA-based COVID-19 vaccine. Case Presentation: An 86-year-old man complained of blurred vision and decreased visual acuity in his right eye 8 days after receiving the second BNT162b2 mRNA-based COVID-19 vaccine and was referred to our hospital. He also had pain with eye movement. Best corrected visual acuity (BCVA) in the right eye was 20/200 and critical flicker frequency dropped to 16 Hz. Relative afferent pupillary defect was positive and central scotomas were observed on visual field analysis. Fundus examination and SD-OCT revealed optic disc swelling and apparent thickening of the retinal nerve fiber layer around the optic disc in the right eye. Although either an increase in CRP or ESR on laboratory tests, demyelinating lesion on MRI, or positive of anti-MOG antibodies or anti-AQP4 antibodies were not observed, fluorescein angiography presented only hyperfluorescence of the optic disc in the right eye, but there were no findings such as papillary deficiency and choroidal delay that would suggest ischemic optic neuropathy. We diagnosed atypical optic neuritis developed after the SARS-CoV-2 mRNA-based vaccination and initiated oral corticosteroid therapy. One month later, the optic disc swelling disappeared and BCVA improved to 20/100; however, the central scotoma remained and no further improvement in visual function OD was obtained. Conclusions: An atypical acute idiopathic optic neuritis can occur after receiving the second vaccination with BNT162b2, which may present a limited response to corticosteroid therapy.

show abstract

“…We read with interest the article by Murgova et al about five patients with ophthalmologic complications after a SARS-CoV-2 vaccination [ 1 ]. Patient-1 experienced right herpetic keratitis and iridocyclitis, patient-2 left anterior uveitis, patient-3 retinal detachment, retinal necrosis, and vitritis, patient-4 anterior ischemic optic neuropathy (AION), and patient-5 left ptosis after subarachnoid bleeding (SAB) (Table 1 ) [ 1 ]. The study is promising but raises concerns that should be discussed.…”

mentioning

confidence: 99%

“…Ptosis, ophthalmoparesis, and pupillary dilatation after SAB is not uncommon and rather a neurological than an ophthalmologic complication after SAB. Unfortunately, nothing is reported about the outcome of these deficits and of SAB [ 1 ].…”

mentioning

confidence: 99%

“…The spectrum of ophthalmologic side effects after SARS-CoV-2 vaccinations is broader than mentioned in the introduction and not only includes uveitis, maculopathy, neuro-retinopathy, or Vogt-Koyanagi-Harada syndrome [ 1 ]. Ophthalmologic complications after SARS-CoV-2 vaccinations additionally reported include neuromyelitis optica (NMO) [ 2 ], myelin associated glycoprotein (MOG) associated disease [ 3 ], acute disseminated encephalomyelitis (ADEM) with optic neuritis [ 4 ], non-specific optic neuritis, and exacerbation of multiple sclerosis (MS) [ 5 ].…”

mentioning

confidence: 99%

See 1 more Smart Citation